Skip to main content
Healthcare

STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more

STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more

Feed excerpt — reported by STAT News

Investors and doctors are intensely following an experimental therapy positioned to rival Dupixent, the top-selling drug in immunology.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.